Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Clin Cancer Res. 2014 Jun 15;20(12):3222–3232. doi: 10.1158/1078-0432.CCR-13-3227

Figure 2.

Figure 2

Low-dose oral HCQ resensitizes resistant breast tumors to antiestrogen therapy. A. LCC9 orthotopic tumors were grown to 25-35 mm2 before treated with TAM, ICI, HCQ, HCQ+ICI, or HCQ+TAM for 5 weeks. Tumors were measured weekly with calipers; % change in tumor area (A) and tumor area (B) was calculated. C. LCC9 tumor weight upon completion of study. MCF7-RR orthotopic tumors were untreated (control) or treated with TAM, HCQ, or HCQ+TAM for 5 weeks. Tumors were measured weekly with calipers and % change in tumor area (D) or tumor area growth curves (E) were calculated. F. Average wet weight of MCF7-RR upon sacrifice.